Las Vegas NV / April 8, 2015 / (VRCI-OTCQB) Verde Science, Inc., a Pharmaceutical Research and Development Company focused on developing a portfolio of cannabinoid based prescription medicines to meet patients needs for a wide range of medical conditions, is pleased to announce the execution of a definitive Research and Development Agreement with the Institute of Chemical Technology of Mumbai, India. Under the terms of the agreement Verde Science researchers and faculty and staff of the University will cooperate on original research with the goal of identifying and developing novel pharmaceutical formulations derived from the marijuana plant for the treatment of specific medical issues.
The Institute of Chemical Technology (ICT), established in 1933 was granted “deemed University status” in 2008 and offers undergraduate, masters, and Ph.D. degree programs in various Chemical Engineering disciplines including the Technology of Pharmaceutical and Fine Chemicals. ICT awards approximately 100 Ph.D. degrees annually.
“This relationship is a significant development for Verde and ICT that will fast track the startup of our initial R&D projects in conjunction with ICT’s prestigious faculty and within ICT’s scientific infrastructure. Our initial projects will focus on the development of efficacious formulations with specific application to the treatment of seizures and pain management, administered with the use of novel delivery systems. Further, this marks our initial step toward becoming a leader in scientific research for the development of advanced formulations of cannabis-based compounds for medical use,” according to Harp Sangha, CEO of Verde Science.
Louis Silver, Verde Science Director of Investor Relations, added, “Many in the medical community have conceded the effectiveness of medical marijuana for the treatment of certain medical issues. However, virtually every credible medical organization has stated that smoking marijuana is deleterious to health. The Verde Science pharmacological model mitigates the risks inherent in the traditional use of marijuana by isolating active ingredients in the marijuana plant and delivering them in safe, medically acceptable forms.”
About Verde Science, Inc. (VRCI-OTCQB)
Verde Science, Inc. (trading symbol VRCI-OTCQB) is an early stage pharmaceutical organization that has built a research team focused on developing a portfolio of cannabinoid prescription medicines to meet patient needs in a wide range of medical conditions. Verde’s scientists have identified a number of promising areas in which to begin its immediate R&D program, which will initially be based in India. The Verde Science team of inter-disciplinary researchers includes scientists in Bioprocess Engineering, Nanotechnology, Molecular Biology, Pharmaceutical Sciences and Bio-Medical Devices that is focused on a streamlined approach to the development of innovative treatment protocols aimed at capturing considerable market share.
For further information please see our investor profile available on our website: www.verdescienceinc.com.
Safe Harbor Statements
Certain information contained in this news release constitutes “forward-looking statements” as such term is used in applicable United States and Canadian laws. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as “expects” or “does not expect,” “is expected,” “anticipates” or “does not anticipate,” “plans,” “estimates,” “intends” or “believes,” or that certain actions, events or results “may,” “could,” “would,” “might” or “will be taken,” “occur,” or “be achieved.” Forward-looking statements are based on the opinions and estimates of management as of the date such statements are made, and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this news release can be found in the Company’s filings with the SEC. Such risks and other factors include, among others, the ability to locate and acquire suitable interests in alternative medicine manufacturing operations on terms acceptable to the Company, the availability of financing on acceptable terms, accidents, labor disputes, acts of God and other risks of the alternative medicine industry including, without limitation, delays in obtaining governmental approvals or permits, title disputes or claims limitations on insurance coverage. The Company believes that the expectations reflected in the forward-looking statements included in this news release are reasonable; however, no assurance can be given that these expectations will prove to be correct, and such forward-looking statements should not be unduly relied upon. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.